. "B Public Workshop on Neuroscience Biomarkers and Biosignatures: Converging Technologies, Emerging Partnerships." Neuroscience Biomarkers and Biosignatures: Converging Technologies, Emerging Partnerships: Workshop Summary. Washington, DC: The National Academies Press, 2008.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Neuroscience Biomarkers and Biosignatures: Converging Technologies, Emerging Partnerships, Workshop Summary
B Public Workshop on Neuroscience Biomarkersand Biosignatures: Converging Technologies,Emerging Partnerships
Monday, February 26, 2007
Lecture Room
The National Academy of Sciences
2100 C Street, NW
Washington, DC
Workshop Objectives
Discuss the most promising, and practical, arenas in neuroscience in which novel biomarkers will have greatest near-term impact on the rate at which new treatments are brought forward for psychiatric and neurological disorders.
Discuss the necessary parameters for such a high-impact biomarker.
Discuss potential partnerships needed to advance the development of biomarkers and biosignatures.
Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole. Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter.
Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 81
Neuroscience Biomarkers and Biosignatures: Converging Technologies, Emerging Partnerships, Workshop Summary
B
Public Workshop on Neuroscience Biomarkers and Biosignatures: Converging Technologies, Emerging Partnerships
Monday, February 26, 2007
Lecture Room
The National Academy of Sciences
2100 C Street, NW
Washington, DC
Workshop Objectives
Discuss the most promising, and practical, arenas in neuroscience in which novel biomarkers will have greatest near-term impact on the rate at which new treatments are brought forward for psychiatric and neurological disorders.
Discuss the necessary parameters for such a high-impact biomarker.
Discuss potential partnerships needed to advance the development of biomarkers and biosignatures.
8:00 a.m.
Continental Breakfast
8:30 a.m.
Welcome and Introductions
ALAN LESHNER
Forum Chair
Chief Executive Officer, AAAS
Executive Publisher, Science
OCR for page 82
Neuroscience Biomarkers and Biosignatures: Converging Technologies, Emerging Partnerships, Workshop Summary
SESSION I:
BIOMARKER AND BIOSIGNATURE PRINCIPLES
8:40 a.m.
Workshop Objective: What parameters should be considered when developing a high-impact biomarker?
DENNIS CHOI, Workshop Chair
Professor of Pharmacology and Experimental Therapeutics
Boston University
8:50 a.m.
Introduction to the fNIH Biomarkers Consortium
TOM INSEL
Director
National Institute of Mental Health
9:10 a.m.
Lessons Learned from Alzheimer’s Disease and the NIA Alzheimer’s Disease Neuroimaging Initiative
WILLIAM POTTER
Vice President
Merck Research Laboratories
Clinical Neuroscience
SESSION II:
POTENTIAL TOOLS FOR BIOMARKER AND BIOSIGNATURE DEVELOPMENT
Session Objective: Discuss which tools and parameters should be considered when developing a high-impact biomarker for the neurological or psychiatric disorders.
ALAN BREIER, Session Chair
Vice President for Medical and Chief Medical Officer
Eli Lilly and Company
9:30 a.m.
What Impact Will the Genomics Field Have on the Immediate or the Near-Term Development of Biomarkers for Nervous System Diseases?
ALLEN ROSES
Senior Vice President
GlaxoSmithKline
OCR for page 83
Neuroscience Biomarkers and Biosignatures: Converging Technologies, Emerging Partnerships, Workshop Summary
9:50 a.m.
What Impact Will Proteomics, Including CSF Analysis, Have on the Near-Term Development of Biomarkers for Nervous System Diseases?
HOWARD SCHULMAN
Vice President
PPD Biomarker Discovery Sciences
10:10 a.m.
BREAK
10:30 a.m.
What Imaging Tools May Be Utilized for the Development of Biomarkers for Nervous System Diseases?
BRUCE ROSEN
Director
Athinoula A. Martinos Center for Biomedical Imaging
Massachusetts General Hospital
10:50 a.m.
Panel Discussion with Meeting Attendees
ALAN BREIER, Session Chair
11:30 a.m.
LUNCH
SESSION III:
PSYCHIATRIC DISEASES AND DRUG ADDICTION DISORDERS
Session Objective: Identify specific areas of psychiatric medicine where the development of a novel biomarker could have a high impact.
TOM INSEL, Session Chair
Director
National Institute of Mental Health
12:30 p.m.
Which Psychiatric Disorders Are Primed for Key Advances in Biomarker Development?
STEVEN HYMAN
Provost
Harvard University
OCR for page 84
Neuroscience Biomarkers and Biosignatures: Converging Technologies, Emerging Partnerships, Workshop Summary
12:45 p.m.
Current and Near-Term Impact of Biomarkers for Depression
HUSSEINI MANJI
Director, Mood and Anxiety Disorders Program
National Institute of Mental Health
1:05 p.m.
Current and Near-Term Impact of Biomarkers for Schizophrenia
DAVID LEWIS
Endowed Professor of Psychiatry
University of Pittsburgh Medical Center
1:25 p.m.
Current and Near-Term Impact of Biomarkers for Disorders of Addiction
NORA VOLKOW
Director
National Institute on Drug Abuse
1:45 p.m.
Panel Discussion with Meeting Attendees
TOM INSEL, Session Chair
2:15 p.m.
BREAK
SESSION IV:
NEUROLOGICAL AND EYE DISEASES
Session Objective: Discuss specific areas of neurological medicine where the development of a novel biomarker could have a high impact.
STORY LANDIS, Session Chair
Director
National Institute of Neurological Disorders and Stroke
2:30 p.m.
Which Neurological Diseases are Primed for Key Advances in Biomarker Development?
IRA SHOULSON
Professor of Neurology
University of Rochester
OCR for page 85
Neuroscience Biomarkers and Biosignatures: Converging Technologies, Emerging Partnerships, Workshop Summary
2:45 p.m.
Current and Near-Term Impact of Biomarkers for Multiple Sclerosis
GAVIN GIOVANNONI
Professor of Neurology
Institute of Cell and Molecular Science
Queen Mary, University of London
3:05 p.m.
Current and Near-Term Impact of Biomarkers for Stroke
STEVEN WARACH
Chief
Section on Stroke Diagnostics and Therapeutics
National Institute of Neurological Disorders and Stroke
3:25 p.m.
Current and Near-Term Impact of Biomarkers for SMA
MEG WINBERG
Research Director
Spinal Muscular Atrophy Foundation
3:45 p.m.
Current and Near-Term Impact of Biomarkers for Retinal Degeneration
PAUL SIEVING
Director
National Eye Institute
4:05 p.m.
Panel Discussion with Meeting Attendees
STORY LANDIS, Session Chair
SESSION V:
REGULATORY CONSIDERATIONS, NEXT STEPS, AND GENERAL DISCUSSION
4:35 p.m.
What Regulatory Considerations Are Important to Developing a Qualified Biomarker?
JANET WOODCOCK
Deputy Commissioner and Chief Medical Officer
Food and Drug Administration
OCR for page 86
Neuroscience Biomarkers and Biosignatures: Converging Technologies, Emerging Partnerships, Workshop Summary
4:55 p.m.
General Discussion
Which biomarkers have the greatest potential for near-term impact on the development of treatments or key diagnostics for nervous system diseases?
What partnerships are needed to move forward?
DENNIS CHOI, Workshop Chair
Professor of Pharmacology & Experimental Therapeutics
Boston University
5:30 p.m.
ADJOURN
